Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:


9/30/2015 New Arrowhead Analyst Issues Updated Diligence and Valuation Report on Hemispherx Biopharma

9/28/2015 Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen® Formulations

9/23/2015 Hemispherx Biopharma Reports Article by Senior Authors from Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen® to Multiple Sclerosis
…. Key may be Ampligen’s Unique Immune Mechanism

9/21/2015 Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome (CFS) Patients Potentially Predictive of Improved Response to Ampligen
….Quality of Life Improvements were related to Exercise Responses to Ampligen

9/17/2015 Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP


Investor Relations:

Charles Jones
CJones & Associates Public Relations